Gayatri Bioorganics held a board meeting, approving its audited financial results for the quarter and year ended March 31, 2026. The company reported a net loss of 0.42 Cr for the quarter and 1.11 Cr for the full year.

The board appointed M/s. Va3 & Co. as Internal Auditors for FY 2026-27. Auditors highlighted substantial disputed statutory dues, including 2.72 Cr in customs duty, 11.47 Cr in excise duty, and 7.47 Cr in income tax demand, which remain outstanding.

This situation warrants attention from shareholders regarding potential financial liabilities.